ArticleJournal of clinical medicine2024
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks.
Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel.Dermatology and therapy · 2026Review
- The State of the Art in Chronic Prurigo Nodularis.Dermatology and therapy · 2026Review
- Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis.Dermatology and therapy · 2026Article
- Chronic Prurigo: Current Knowledge, Treatment Strategies, Future Perspectives, and Unmet Needs.Acta dermato-venereologica · 2026Article
- Experience in the management of real-world patients with chronic prurigo nodularis in a dermatology setting: results from the ECOSPIN Spanish survey-based study.Frontiers in medicine · 2026Article
- Severe non-atopic prurigo nodularis in an otherwise healthy elderly patient: rapid multidimensional response to dupilumab.Frontiers in pharmacology · 2026Article
- Dupilumab: an Additional Arrow in the Quiver for Prurigo Nodularis? Data From a Real-Life Setting.Dermatology practical & conceptual · 2025Article
- Cost-effectiveness Analysis of Dupilumab for the Treatment of Adult Patients with Severe Prurigo Nodularis in Italy.Acta dermato-venereologica · 2025Article
- Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment.Acta dermato-venereologica · 2025Article
- Cutaneous Adverse Events Following Nemolizumab Administration: A Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.